Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts Holding Company

https://www.express-scripts.com/

Latest From Express Scripts Holding Company

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies

Time To Tip the Scales? Humira Biosimilars And The Limitations Of Competition In US Health Care

In year two, Humira biosimilar uptake – or the lack thereof – continues to build the case for policy reform to incentivize use of cheaper biologics in the outpatient setting.

Biosimilars Reimbursement

‘Essential Benefit’ Drug Coverage Protections Is Next Priority For Patient Group Behind Copay Accumulator Victory

HIV+Hepatitis Policy Institute provides CMS with a long list of plan sponsors and vendors that appear to be engaged in the practice, which the group argues circumvents the cost sharing protections provided by the Affordable Care Act for hundreds of drugs.

Reimbursement Policy

Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude In 2023

With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.

Business Strategies Companies
See All

Company Information

  • Industry
  • Services
  • Services
    • Pharmacy Services, PBMs
  • Other Names / Subsidiaries
    • Aristotle Holding, Inc.
    • Cigna Corporation
    • Express Scripts, Inc.
    • Medco Health Solutions, Inc.
UsernamePublicRestriction

Register